Kadimastem (Israel) Top Management
| KDST Stock | ILA 496.00 11.60 2.39% |
Kadimastem employs about 23 people. The company is managed by 23 executives with a total tenure of roughly 162 years, averaging almost 7.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Kadimastem's management performance can provide insight into the company performance.
| Ram Epstein CEO Chief Executive Officer, Director |
| Eli Opper Chairman Chairman of the Board |
Kadimastem |
Kadimastem Management Team Effectiveness
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Kadimastem Workforce Comparison
Kadimastem is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 5,571. Kadimastem adds roughly 23.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Kadimastem Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Kadimastem Price Series Summation is a cross summation of Kadimastem price series and its benchmark/peer.
Kadimastem Notable Stakeholders
A Kadimastem stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kadimastem often face trade-offs trying to please all of them. Kadimastem's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kadimastem's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ram Epstein | Chief Executive Officer, Director | Profile | |
| Eli Opper | Chairman of the Board | Profile | |
| Yossi Nizhar | Vice President - Finance | Profile | |
| Michal Harel | Vice President - Research & Development-ALS & Neurodegenerative Diseases | Profile | |
| Neta Lavon | Vice President - Operations | Profile | |
| Arye Hasson | Executive Vice President-Research & Development | Profile | |
| Yehuda Feinberg | Vice President - Finance | Profile | |
| Keren Tzlill | External Director | Profile | |
| David Sultan | Independent Director | Profile | |
| Michel Revel | Chief Scientific Officer-Services Provider, Director | Profile | |
| Joseph Eldor | Director | Profile | |
| Avi Bzura | External Director | Profile | |
| Abraham Meizler | Director | Profile | |
| Adina Makover | External Director | Profile | |
| Yigal Fatran | Director | Profile | |
| Julien Ruggieri | Director | Profile | |
| Ilan Hadar | External Director | Profile | |
| Arik Hasson | Exec Devel | Profile | |
| Yossi BenYossef | Honorary Consultant | Profile | |
| Michal Izrael | VP Diseases | Profile | |
| Asaf Shiloni | Chief Officer | Profile | |
| Pr MD | Chief CoFounder | Profile | |
| Ziv Ironi | External Director | Profile |
About Kadimastem Management Performance
The success or failure of an entity such as Kadimastem often depends on how effective the management is. Kadimastem management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kadimastem management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kadimastem management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 28 people.
The data published in Kadimastem's official financial statements usually reflect Kadimastem's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kadimastem. For example, before you start analyzing numbers published by Kadimastem accountants, it's critical to develop an understanding of what Kadimastem's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Kadimastem's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kadimastem's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kadimastem's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kadimastem. Please utilize our Beneish M Score to check the likelihood of Kadimastem's management manipulating its earnings.
Kadimastem Workforce Analysis
Traditionally, organizations such as Kadimastem use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kadimastem within its industry.Kadimastem Manpower Efficiency
Return on Kadimastem Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 1.1M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kadimastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |